Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): Design and rationale of a double-blind, placebocontrolled randomised multicenter trial [ISRCTN38327949]

被引：67

作者：

Besselink M.G.H. ^{[1
]}

Timmerman H.M. ^{[1
]}

Buskens E. ^{[2
]}

Nieuwenhuijs V.B. ^{[1
]}

Akkermans L.M.A. ^{[1
]}

Gooszen H.G. ^{[1
]}

机构：

[1] Department of Surgery, University Medical Center Utrecht, HP G04.228, 3508 GA Utrecht

[2] Julius Ctr. Hlth. Sci. Prim. Care, University Medical Center Utrecht, 3500 AB Utrecht

来源：

BMC Surgery | / 4卷 / 1期

关键词：

Pancreatitis; Acute Pancreatitis; Infectious Complication; Severe Acute Pancreatitis; Pancreatic Necrosis;

D O I：

10.1186/1471-2482-4-12

中图分类号：

学科分类号：

摘要：

Background: Infectious complications are the major cause of death in acute pancreatitis. Small bowel bacterial overgrowth and subsequent bacterial translocation are held responsible for the vast majority of these infections. Goal of this study is to determine whether selected probiotics are capable of preventing infectious complications without the disadvantages of antibiotic prophylaxis; antibiotic resistance and fungal overgrowth. Methods/design: PROPATRIA is a double-blind, placebo-controlled randomised multicenter trial in which 200 patients will be randomly allocated to a multispecies probiotic preparation (Ecologic 641) or placebo. The study is performed in all 8 Dutch University Hospitals and 7 non-University hospitals. The study-product is administered twice daily through a nasojejunal tube for 28 days or until discharge. Patients eligible for randomisation are adult patients with a first onset of predicted severe acute pancreatitis: Imrie criteria 3 or more, CRP 150 mg/L or more, APACHE II score 8 or more. Exclusion criteria are post-ERCP pancreatitis, malignancy, infection/sepsis caused by a second disease, intra-operative diagnosis of pancreatitis and use of probiotics during the study. Administration of the study product is started within 72 hours after onset of abdominal pain. The primary endpoint is the total number of infectious complications. Secondary endpoints are mortality, necrosectomy, antibiotic resistance, hospital stay and adverse events. To demonstrate that probiotic prophylaxis reduces the proportion of patients with infectious complications from 50% to 30%, with alpha 0,05 and power 80%, a total sample size of 200 patients was calculated. Conclusion: The PROPATRIA study is aimed to show a reduction in infectious complications due to early enteral use of multispecies probiotics in severe acute pancreatitis. © 2004 Besselink et al; licensee BioMed Central Ltd.

引用

共 40 条

[1] Baron T.H., Morgan D.E., Acute necrotizing pancreatitis, N Engl JMed, 340, pp. 1412-1417, (1999)
[2] Beger H.G., Bittner R., Block S., Buchler M., Bacterial contamination of pancreatic necrosis. A prospective clinical study, Gastroenterology, 91, pp. 433-438, (1986)
[3] Bradley E.L., Allen K., A prospective longitudinal study of observation versus surgical intervention in th management of necrotizing pancreatitis, Am J Surg, 161, pp. 19-25, (1991)
[4] Buchler M.W., Gloor B., Muller C.A., Friess H., Seiler C.A., Uhl W., Acute necrotizing pancreatitis: Treatment strategy according to the status of infection, Ann Surg, 232, pp. 619-626, (2000)
[5] Dervenis C., Smailis D., Hatzitheoklitos E., Bacterial translocation and its prevention in acute pancreatitis, J Hepatobiliary Pancreat Surg, 10, pp. 415-418, (2003)
[6] Nieuwenhuijs V.B., Verheem A., Duijvenbode-Beumer H., Visser M.R., Verhoef J., Gooszen H.G., Et al., The role of interdigestive small bowel motility in the regulation of gut microflora, bacterial overgrowth, and bacterial translocation in rats, Ann Surg, 228, pp. 188-193, (1998)
[7] Nieuwenhuijs V.B., Van Dijk J.E., Gooszen H.G., Akkermans L.M., Obstructive jaundice, bacterial translocation and interdigestive small-bowel motility in rats, Digestion, 62, pp. 255-261, (2000)
[8] Van Felius I.D., Akkermans L.M., Bosscha K., Verheem A., Harmsen W., Visser M.R., Et al., Interdigestive small bowel motility and duodenal bacterial overgrowth in experimental acute pancreatitis, Neurogastroenterol Motil, 15, pp. 267-276, (2003)
[9] Van Minnen L.P., Nieuwenhuijs V.B., De Bruijn M.Th., Visser M.R., Van Dijk J.E., Akkermans L.M.A., Gooszen H.G., The Role of the Large Bowel in the Infection of Pancretic Necrosis during Experimental Acute Pancreatitis, (2004)
[10] Delcenserie R., Yzet T., Ducroix J.P., Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis, Pancreas, 13, pp. 198-201, (1996)

← 1 2 3 4 →